Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

chronic lung disease

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

- PMLiVE

AZ adds another Ionis drug in $330m kidney disease deal

The candidate targets a genetically associated form of the condition

The ‘Million Hour Challenge’

AstraZeneca employees save two million hours through simplification

- PMLiVE

Novartis negotiates ex-US rights to Spark gene therapy

Strikes $170m deal for Luxturna

- PMLiVE

Pfizer buys into Sangamo’s motor neuron disease gene therapy

The pharma giant will pay $12m upfront and $150m in potential milestones

- PMLiVE

NICE backs GSK’s €594k gene therapy for rare disease

The treatment offers 'bubble baby' patients an alternative to a stem cell transplant

- PMLiVE

Spark sets Luxturna price, igniting US affordability debate

The IRD treatment is set to cost patients $425,000 per eye

- PMLiVE

Spark’s Luxturna becomes US’s first approved gene therapy

FDA says its move 'reinforces the potential of this breakthrough'

AstraZeneca AZ

Clock starts ticking on AZ’s first-line lung cancer filing in US

FDA priority review of oncology treatment Tagrisso begins

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

AstraZeneca AZ

AZ speeds first-line lung cancer filing for Tagrisso to EMA

As FLAURA trial results show boosted progression-free survival

- PMLiVE

Gene therapy

When will it deliver?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links